139 related articles for article (PubMed ID: 7755488)
1. Accumulation of 3-(phenylamino)alanine, a constituent in L-tryptophan products implicated in eosinophilia-myalgia syndrome, in blood and organs of the Lewis rats.
Adachi J; Gomez M; Smith CC; Sternberg EM
Arch Toxicol; 1995; 69(4):266-70. PubMed ID: 7755488
[TBL] [Abstract][Full Text] [Related]
2. Identification of four metabolites of 3-(phenylamino)alanine, a constituent in L-tryptophan products implicated in eosinophilia-myalgia syndrome, in rats.
Adachi J; Mio T; Ueno Y; Naito T; Nishimura A; Fujiwara S; Sumino K; Tatsuno Y
Arch Toxicol; 1994; 68(8):500-5. PubMed ID: 7802590
[TBL] [Abstract][Full Text] [Related]
3. Subchronic toxicity of 3-phenylamino alanine, an impurity in L-tryptophan reported to be associated with eosinophilia-myalgia syndrome.
Sato F; Hagiwara Y; Kawase Y
Arch Toxicol; 1995; 69(7):444-9. PubMed ID: 8526739
[TBL] [Abstract][Full Text] [Related]
4. 3-(Phenylamino)alanine, a novel aniline-derived amino acid associated with the eosinophilia-myalgia syndrome: a link to the toxic oil syndrome?
Mayeno AN; Belongia EA; Lin F; Lundy SK; Gleich GJ
Mayo Clin Proc; 1992 Dec; 67(12):1134-9. PubMed ID: 1469924
[TBL] [Abstract][Full Text] [Related]
5. Biotransformation of 3-(phenylamino)-1,2-propanediol to 3-(phenylamino)alanine: a chemical link between toxic oil syndrome and eosinophilia-myalgia syndrome.
Mayeno AN; Benson LM; Naylor S; Colberg-Beers M; Puchalski JT; Gleich GJ
Chem Res Toxicol; 1995; 8(7):911-6. PubMed ID: 8555405
[TBL] [Abstract][Full Text] [Related]
6. Generation of quinoneimine intermediates in the bioactivation of 3-(N-phenylamino)alanine (PAA) by human liver microsomes: a potential link between eosinophilia-myalgia syndrome and toxic oil syndrome.
MartÃnez-Cabot A; Messeguer A
Chem Res Toxicol; 2007 Oct; 20(10):1556-62. PubMed ID: 17892268
[TBL] [Abstract][Full Text] [Related]
7. Accumulation of 1-methyl-tetrahydro-beta-carboline-3-carboxylic acid in blood and organs of rat. A possible causative substance of eosinophilia-myalgia syndrome associated with ingestion of L-tryptophan.
Ogawa Y; Adachi J; Tatsuno Y
Arch Toxicol; 1993; 67(4):290-3. PubMed ID: 8517786
[TBL] [Abstract][Full Text] [Related]
8. Metabolism and distribution in the rat of peak E substance, a constituent in L-tryptophan product implicated in eosinophilia-myalgia syndrome.
Adachi J; Naito T; Ueno Y; Ogawa Y; Ninomiya I; Tatsuno Y
Arch Toxicol; 1993; 67(4):284-9. PubMed ID: 8517785
[TBL] [Abstract][Full Text] [Related]
9. Effect of 3-phenylamino-L-alanine on tryptophan binding to rat hepatic nuclear envelopes.
Sidransky H; Verney E; Cosgrove JW; Latham PS
Toxicology; 1994 Jan; 86(1-2):135-45. PubMed ID: 8134920
[TBL] [Abstract][Full Text] [Related]
10. A comparative study of tissue distribution and excretion among three substances implicated in eosinophilia-myalgia syndrome.
Adachi J; Ueno Y; Tatsuno Y; Gomez M; Smith CC; Sternberg EM
Adv Exp Med Biol; 1996; 398():365-70. PubMed ID: 8906290
[No Abstract] [Full Text] [Related]
11. On-line HPLC-tandem mass spectrometry analysis of contaminants of L-tryptophan associated with the onset of the eosinophilia-myalgia syndrome.
Williamson BL; Benson LM; Tomlinson AJ; Mayeno AN; Gleich GJ; Naylor S
Toxicol Lett; 1997 Jul; 92(2):139-48. PubMed ID: 9295237
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and analysis of contaminants in ems-related tryptophan.
Steinhart H; van Wickern B; Meyer K; Simat T
Adv Exp Med Biol; 1996; 398():667-75. PubMed ID: 8906342
[No Abstract] [Full Text] [Related]
13. L-tryptophan implicated in human eosinophilia-myalgia syndrome causes fasciitis and perimyositis in the Lewis rat.
Crofford LJ; Rader JI; Dalakas MC; Hill RH; Page SW; Needham LL; Brady LS; Heyes MP; Wilder RL; Gold PW
J Clin Invest; 1990 Nov; 86(5):1757-63. PubMed ID: 2243145
[TBL] [Abstract][Full Text] [Related]
14. Tetrahydro-beta-carboline-3-carboxylic acids and contaminants of L-tryptophan.
Adachi J; Asano M; Ueno Y
J Chromatogr A; 2000 Jun; 881(1-2):501-15. PubMed ID: 10905731
[TBL] [Abstract][Full Text] [Related]
15. Structural characterization of case-associated contaminants peak C and FF in L-tryptophan implicated in eosinophilia-myalgia syndrome.
Naylor S; Williamson BL; Johnson KL; Gleich GJ
Adv Exp Med Biol; 1999; 467():453-60. PubMed ID: 10721088
[TBL] [Abstract][Full Text] [Related]
16. 1,1'-Ethylidenebis[tryptophan] induces pathologic alterations in muscle similar to those observed in the eosinophilia-myalgia syndrome.
Emslie-Smith AM; Mayeno AN; Nakano S; Gleich GJ; Engel AG
Neurology; 1994 Dec; 44(12):2390-2. PubMed ID: 7991132
[TBL] [Abstract][Full Text] [Related]
17. 1,1'-Ethylidenebis[L-tryptophan], a contaminant implicated in L-tryptophan eosinophilia myalgia syndrome, suppresses mRNA expression of hypothalamic corticotropin-releasing hormone in Lewis (LEW/N) rat brain.
Brady LS; Page SW; Thomas FS; Rader JL; Lynn AB; Misiewicz-Poltorak B; Zelazowski E; Crofford LJ; Zelazowski P; Smith C
Neuroimmunomodulation; 1994 Jan; 1(1):59-65. PubMed ID: 8528886
[TBL] [Abstract][Full Text] [Related]
18. Rapid HPLC screening method for contaminants found in implicated L-tryptophan associated with eosinophilia myalgia syndrome and adulterated rapeseed oil associated with toxic oil syndrome.
Williamson BL; Tomlinson AJ; Hurth KM; Posada de la Paz M; Gleich GJ; Naylor S
Biomed Chromatogr; 1998; 12(5):255-61. PubMed ID: 9787895
[TBL] [Abstract][Full Text] [Related]
19. Enhanced collagen synthesis and transcription by peak E, a contaminant of L-tryptophan preparations associated with the eosinophilia myalgia syndrome epidemic.
Takagi H; Ochoa MS; Zhou L; Helfman T; Murata H; Falanga V
J Clin Invest; 1995 Nov; 96(5):2120-5. PubMed ID: 7593596
[TBL] [Abstract][Full Text] [Related]
20. 3-anilino-L-alanine, structural determination of UV-5, a contaminant in EMS-associated L-tryptophan samples.
Goda Y; Suzuki J; Maitani T; Yoshihira K; Takeda M; Uchiyama M
Chem Pharm Bull (Tokyo); 1992 Aug; 40(8):2236-8. PubMed ID: 1423790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
